Jerome Wielens

Jerome Wielens

Auto-generated profile, based on publicly available information

Jerome Wielens

Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, 381 Royal Parade, Parkville, Victoria, 3052, Australia

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2014 in Nature Reviews Cancer
Verified
Journal Article
Closed access
TNTracy L. Nero
Tracy L. Nero
CMCraig Morton
Craig Morton
Jessica HolienJessica Holien
Jessica Holien
JWJerome Wielens
Jerome Wielens
MPMichael Parker
Michael Parker

23 April 2014 in Scientific Reports
Verified
Journal Article
Open access
PDF file
DADavid Ascher
David Ascher
JWJerome Wielens
Jerome Wielens
TNTracy L. Nero
Tracy L. Nero
LDLarissa Doughty
Larissa Doughty
CMCraig Morton
Craig Morton
MPMichael Parker
Michael Parker
Hepatitis C virus (HCV) infection affects more than 170 million people. The high genetic variability of HCV and the rapid development of drug-resistant strains are driving the urgent search for new direct-acting antiviral agents. A new class of agents has recently been developed that are believed to target the HCV protein NS5A although precisely where they interact and how they affect function is unknown. Here we describe an in vitro assay based on microscale thermophoresis and demonstrate that two clinically relevant inhibitors bind tightly to NS5A domain 1 and inhibit RNA binding. Conversely, RNA binding inhibits compound binding. The compounds bind more weakly to known resistance mutants L31V and Y93H. The compounds do not affect NS5A dimerisation. We propose that current NS5A inhibitors act by favouring a dimeric structure of NS5A that does not bind RNA.

1 June 2009 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
JPJason J Paxman
Jason J Paxman
NBNatalie Borg
Natalie Borg
JHJames Horne
James Horne
PTPhilip Thompson
Philip Thompson
YCYanni Chin
Yanni Chin
MSMartin J. Scanlon
Martin J. Scanlon
Oxidative protein folding in Gram-negative bacteria results in the formation of disulfide bonds between pairs of cysteine residues. This is a multistep process in which the dithiol-disulfide oxidoreductase enzyme, DsbA, plays a central role. The structure of DsbA comprises an all helical domain of unknown function and a thioredoxin domain, where active site cysteines shuttle between an oxidized, substrate-bound, reduced form and a DsbB-bound form, where DsbB is a membrane protein that reoxidizes DsbA. Most DsbA enzymes interact with a wide variety of reduced substrates and show little specificity. However, a number of DsbA enzymes have now been identified that have narrow substrate repertoires and appear to interact specifically with a smaller number of substrates. The transient nature of the DsbA-substrate complex has hampered our understanding of the factors that govern the interaction of DsbA enzymes with their substrates. Here we report the crystal structure of a complex between Escherichia coli DsbA and a peptide with a sequence derived from a substrate. The binding site identified in the DsbA-peptide complex was distinct from that observed for DsbB in the DsbA-DsbB complex. The structure revealed details of the DsbA-peptide interaction and suggested a mechanism by which DsbA can simultaneously show broad specificity for substrates yet exhibit specificity for DsbB. This mode of binding was supported by solution nuclear magnetic resonance data as well as functional data, which demonstrated that the substrate specificity of DsbA could be modified via changes at the binding interface identified in the structure of the complex.

1 February 2013 in SLAS Discovery
Verified
Journal Article
Open access
JWJerome Wielens
Jerome Wielens
SHStephen J. Headey
Stephen J. Headey
DRDavid I. Rhodes
David I. Rhodes
RMRoger Mulder
Roger Mulder
ODOlan Dolezal
Olan Dolezal
MSMartin J. Scanlon
Martin J. Scanlon
Fragment screening is becoming widely accepted as a technique to identify hit compounds for the development of novel lead compounds. In neighboring laboratories, we have recently, and independently, performed a fragment screening campaign on the HIV-1 integrase core domain (IN) using similar commercially purchased fragment libraries. The two campaigns used different screening methods for the preliminary identification of fragment hits; one used saturation transfer difference nuclear magnetic resonance spectroscopy (STD-NMR), and the other used surface plasmon resonance (SPR) spectroscopy. Both initial screens were followed by X-ray crystallography. Using the STD-NMR/X-ray approach, 15 IN/fragment complexes were identified, whereas the SPR/X-ray approach found 6 complexes. In this article, we compare the approaches that were taken by each group and the results obtained, and we look at what factors could potentially influence the final results. We find that despite using different approaches with little overlap of initial hits, both approaches identified binding sites on IN that provided a basis for fragment-based lead discovery and further lead development. Comparison of hits identified in the two studies highlights a key role for both the conditions under which fragment binding is measured and the criteria selected to classify hits.

1 May 2005 in Journal of Biological Chemistry
Verified
Journal Article
Open access
TVTony Velkov
Tony Velkov
SCSara Chuang
Sara Chuang
JWJerome Wielens
Jerome Wielens
HSHarry Sakellaris
Harry Sakellaris
WCWilliam N. Charman
William N. Charman
MSMartin J. Scanlon
Martin J. Scanlon
Intestinal fatty acid-binding protein (I-FABP) is a small protein that binds long-chain dietary fatty acids in the cytosol of the columnar absorptive epithelial cells (enterocytes) of the intestine. The binding cavity of I-FABP is much larger than is necessary to bind a fatty acid molecule, which suggests that the protein may be able to bind other hydrophobic and amphipathic ligands such as lipophilic drugs. Herein we describe the binding of three structurally diverse lipophilic drugs, bezafibrate, ibuprofen (both R- and S-isomers) and nitrazepam to I-FABP. The rank order of affinity for I-FABP determined for these compounds was found to be R-ibuprofen approximately bezafibrate > S-ibuprofen >> nitrazepam. The binding affinities were not directly related to aqueous solubility or partition coefficient of the compounds; however, the freely water-soluble drug diltiazem showed no affinity for I-FABP. Drug-I-FABP interaction interfaces were defined by analysis of chemical shift perturbations in NMR spectra, which revealed that the drugs bound within the central fatty acid binding cavity. Each drug participated in a different set of interactions within the cavity; however, a number of common contacts were observed with residues also involved in fatty acid binding. These data suggest that the binding of non-fatty acid lipophilic drugs to I-FABP may increase the cytosolic solubility of these compounds and thereby facilitate drug transport from the intestinal lumen across the enterocyte to sites of distribution and metabolism.

1 May 2005 in Journal of Computer-Aided Molecular Design
Verified
Journal Article
Closed access
PDF file
JWJerome Wielens
Jerome Wielens
ICIan T. Crosby
Ian T. Crosby
DCDavid Chalmers
David Chalmers